Publications
13
Citations
353
Est. group size
~2
Recurring co-author estimate
Active years
6
Publishing since 2021
Typically publishes in teams of ~11 · 0% small-team papers (≤3 authors) · across 6 venues
- Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity
Proceedings of the National Academy of Sciences · 2024
- Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
ChemMedChem · 2024
- Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19
Journal of Medicinal Chemistry · 2022
- Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
Nature Communications · 2022
- An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer
Nature Cancer · 2022
- Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites
Journal of Medicinal Chemistry · 2021
- Nature Communications×2
- Journal of Medicinal Chemistry×2
- eLife×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Nature Cancer×1
- Evan Rogers
Medicine · University of Michigan
- Lindsey D. Hughes
Medicine · University of Michigan
- Mukesh K. Nyati
Medicine · University of Michigan
- Tamio Okimoto
Medicine · The Ohio State University
- Bryan J. Schneider
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile